Onkoloji Hastalarında Kemoterapi öncesi HBsAg, AntiHBs ve izole AntiHBc pozitiflik oranları

Year 2019, Volume: 12 Issue: 3, 407 - 410, 30.09.2019

Nagehan Didem Sarı Rıza Umar Gürsu

https://doi.org/10.31362/patd.551620

Abstract

AAmaç:Onkoloji
hastalarında uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir. Bu
çalışmada amacımız hastanemiz onkoloji polikliniğinde takip edilen ve
kemoterapi alması planlanan hastalarda kemoterapi öncesinde HBV enfeksiyonu
açısından yapılan tarama sonuçlarını değerlendirmektir.

Yöntem:Bu
çalışmada Ocak 2014-Aralık 2018 tarihleri arasında xxxxxxxx Hastanesi Medikal
Onkoloji Polikliniği’ne başvuran ve kemoterapi alması planlanan, HBV
serolojileri taranmış, 544 hasta değerlendirmeye alındı. Hastaların yaş,
onkolojik tanıları, HBV enfeksiyonu açısından HBsAg, AntiHBs ve AntiHBc Ig G
sonuçları retrospektif olarak tarandı.

Bulgular:Hastanın
tamamından HBsAg istenmiş olduğu belirlenmiş olup, 16’sında (16/544) %2,94
HBsAg pozitifliği görüldü. AntiHBs istenen hasta sayısının 158 olduğu ve bu
hastalardan 51’nin pozitif %32,27 
(51/158) olduğu, İzole AntiHBcIg G pozitiflik oranının ise 4/50 (%8)
olduğu belirlendi. HBsAg pozitif 16 hastanın malignite dağılımlarına
bakıldığında en sık akciğer ve gastrointestinal kanser olduğu görüldü.

Sonuç:Kemoterapi
planlanan hastalarda reaktivasyon, karaciğer yetmezliği, tedaviye ara verme
gibi risk faktörleri de göz önüne alınarak hastaların HBV enfeksiyonu açısından
taranması ve immunsüpresif tedavi uygulayan hekimlerin bu konuda
farkındalığının arttırılması gerektiğini düşünmekteyiz.

Keywords

onkoloji, Kemoterapi, HBV

The Positivity Ratios of HBsAg, AntiHBs and isolated anti-HB in patients with canser Prior to Chemotherapy

Abstract

Objective:Chemotherapy
in oncology patients may cause HBV reactivation. The aim of this study was to
evaluate screening results for HBV infection before chemotherapy in patients
who are being followed-up and planned to receive chemotherapy in oncology
clinic.

Methods:This
study included 544 patients who are admitted to the xxxxxxxx Hospital Medical
Oncology Outpatient Clinic between January 2014 and December 2018, planned to
receive chemotherapy.  Age, diagnoses,
HBsAg, AntiHBs and AntiHbcIg G results were screened retrospectively for HBV
infection.

Result:When a
total of 544 patients who were planned to receive chemotherapy were analyzed
with regard to canser type, lung and gastrointestinal cancers were found to be
most common.  It was determined that
HBsAg was required in all. HBsAg positivity ratio of our patients was 2,94 %
(16/544) , anti-HBs positivity was found as 
%32,27  (51/158) , the rate of
Isolated AntiHBc Ig G was 4/50 (8%) .

     
Result of this study considering the risk factors such as reactivation,
hepatic failure, interruption of treatment in patients who are scheduled for
chemotherapy, we think that the patients should be screened for HBV infection
and the awareness of physicians who apply immunosuppressive treatment study should
be increased.

Keywords

oncology, Chemotherapy, HBV

References

• KaynaklarReferans 1- Loomba R,Liang TJ. HepatitisB rectivation associated with suppresive and biological modifier therapies: current concepts,management strategies,and future directions. Gastroenterology 2017;152:1297-309
• Referans 2- European association for the study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virüs infection.J Hepatol 2017;67:370-98.
• Referans 3- Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy;diagnosis and management.J Gastroenterol 2010;25:864-71.
• Referans 4- Yeo W,Johnson PJ,Diagnosis, prevention and management of hepatitis B reaktivation during anticancer therapy. Hepatology 2006;43;209-20.
• Referans 5- Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148(1): 215-9.
• Referans 6- Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol. 2009;26: 386-92.
• Referans 7- Meidani M, Rostami M, Hemmati S, et al. Screening and evaluation of chronic and occult Hepatitis B in chemo - radiotherapy patients with cancer. Adv Biomed Res. 2016;5:85.
• Referans 8- İnci A, Açıkgöz Ö,Kalaycı M, Ülker V, meme ve jinekolojik kanserli hastalarda kemoterapi öncesi HBs Ag, Anti HBs ve izole Anti HBc pozitiflik oranları Jof Cl.and exp.Inv.2018;9:91-94
• Referans 9- Engin B, Günay S, Binicier ÖM, Derviş Hakim G,Yıldız C, Paköz ZB. İmmünsüpresif hastalarda hepatit B virüs tarama sıklığı ve gerçek yaşam verileri . FNG & Bilim Tıp Dergisi 2016;2:256-9.
• Referans 10- Kose Ş, Olmezoğlu A, Gozaydın A, Ece G. Seroprevalans of Hepatitis B and C among Oncology Patients in Turkey .J Health Popul Nutr.2011 Dec;29(6):652-655
• Referans 11- Oguz A, Aykas F, Unal D, et al. Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy. Asian Pac J Cancer Prev. 2014;15:1411-4.
• Referans 12- Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H, Hu HD. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015;114:164-73.
• Referans 13- Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion. 2001;41:1093–99
• Referans 14- Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H, et al. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002;100:2637–41.
• Referans 15- Dreier J, Kröger M, Diekmann J, Götting C, Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med. 2004;14:97–103.